Brief: Medipal Recieves Orphan Drug Designation For JR-446 For Mucopolysaccharidosis Type IIIB
29/09/2025 18:01
Sept 29 (Reuters) - MEDIPAL: MEDIPAL - NOTICE OF ORPHAN DRUG DESIGNATION FOR JR-446 FOR MUCOPOLYSACCHARIDOSIS TYPE IIIB BY MINISTRY OF HEALTH, LABOUR AND WELFARE OF JAPAN ((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results